Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Albertini

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
JAMA|June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialRichard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 17, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024Susan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
JAMA|June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialRichard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 17, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024Susan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Pageof 7